NCT04781387View on ClinicalTrials.gov

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

April 16, 2024

Study Completion Date

April 16, 2024

Conditions
Clostridioides Difficile Infection
Interventions
DRUG

CRS3123

Study drug dosed PO BID for a total of 10 days

DRUG

Active Comparator

Active comparator dosed PO QID for 10 days

Trial Locations (20)

10467

134, The Bronx

15401

114, Uniontown

27514

147, Chapel Hill

30060

140, Marietta

33125

146, Miami

33144

122, Miami

48073

130, Royal Oak

59701

128, Butte

60190

129, Winfield

63304

139, Weldon Spring

77079

123, Houston

78229

101, San Antonio

78613

104, Cedar Park

83404

110, Idaho Falls

91345

143, Mission Hills

92835

131, Fullerton

92868

138, Orange

93534

117, Lancaster

T2N2T9

116, Calgary

N6A 4V2

120, London

Sponsors

Lead Sponsor

Crestone, Inc
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Crestone, Inc

INDUSTRY